Back to Search
Start Over
Placental transfer of rosiglitazone in the ex vivo human perfusion model
- Source :
- American journal of obstetrics and gynecology. 195(6)
- Publication Year :
- 2005
-
Abstract
- Objective The objective of the study was to determine transplacental passage of rosiglitazone (Avandia) using the ex vivo human placental model. Study design Perfusion studies were performed on 10 placentas from term, uncomplicated deliveries. Concentrations typical for an 8-mg oral dose (216 to 692 ng/mL) as well as 2- to 3-fold increased concentrations were tested (734 to 1261 ng/mL). Transfer of rosiglitazone was assessed and accumulation was determined using the 14 C-antipyrine reference method. Results The clearance index for low and high concentrations were 0.14 ± 0.04 and 0.20 ± 0.08, suggesting that the drug passes through the placenta at a relatively low rate. Fetal accumulation occurred in only 1 of 5 placentas at 16.4 ng/mL (5%) for the 8-mg dose and in 2 of 5 placentas ranging from 0 to 74 ng/mL (5% to 8%) at higher concentrations. Conclusion There is minimal transfer and fetal accumulation of rosiglitazone according to the ex vivo human perfusion model.
- Subjects :
- medicine.medical_specialty
Placenta
Administration, Oral
In Vitro Techniques
Models, Biological
Rosiglitazone
Fetus
In vivo
Pregnancy
Internal medicine
Medicine
Humans
Hypoglycemic Agents
Dose-Response Relationship, Drug
business.industry
Osmolar Concentration
Obstetrics and Gynecology
Transplacental
Dose–response relationship
Endocrinology
medicine.anatomical_structure
Female
Thiazolidinediones
business
Perfusion
Ex vivo
medicine.drug
Subjects
Details
- ISSN :
- 10976868
- Volume :
- 195
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- American journal of obstetrics and gynecology
- Accession number :
- edsair.doi.dedup.....1faefa9d4b9b29e56795d1694e6258f0